Surajit Pal, Pharma Analyst at Prabhudas Lilladher told CNBC-TV18 that this is good news for Aurobindo as this plant has almost 26 percent of pending approvals which are important drivers for its US business.
first published: Sep 19, 2016 02:56 pm
A collection of the most-viewed Moneycontrol videos.
You are already a Moneycontrol Pro user.

